Eli Lilly (LLY) Operating Leases (2019)

Eli Lilly (LLY) reported Operating Leases of $608.4 million for Q4 2019, down 0.51% quarter-over-quarter from $611.5 million in Q3 2019.

Eli Lilly (LLY) Operating Leases (2019) Analysis & Trends

Eli Lilly has reported Operating Leases for 1 years, with the latest figure at $608.4 million in Q4 2019.

For the quarter ending Q4 2019, Operating Leases changed N/A year-over-year to $608.4 million; the trailing twelve-month figure through Dec 2019 stood at $608.4 million (changed N/A YoY), and the FY2019 full-year result was $608.4 million, changed N/A from the prior year.
Operating Leases for Q4 2019 stood at $608.4 million, down from $611.5 million in the prior quarter.
The five-year high for Operating Leases was $621.9 million in Q1 2019, with the low at $503.3 million in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn
10	Novartis Ag	108.28 Bn	107.60 Bn	-

Download Data